For IL-6, its serum level increases in human patients with type 2 diabetes [39], and obesity-based GDM mice also show renal damage, with increased blood IL-6 levels and activated MAPK signaling in the kidney [15]. Here, IL6 is linked to obesity due to melanocortin 4 receptor deficiency.